Search
Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma
- OPACC
- Jun 16, 2022
- 1 min read
The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Komentar